Baxter International (BAX) to Release Earnings on Thursday

Baxter International (NYSE:BAX) is expected to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Baxter International to post earnings of $0.52 per share and revenue of $2.67 billion for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Baxter International Stock Performance

Shares of BAX opened at $30.61 on Wednesday. The firm’s 50 day moving average price is $30.70 and its two-hundred day moving average price is $34.38. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. The firm has a market cap of $15.63 billion, a P/E ratio of 153.03, a PEG ratio of 9.83 and a beta of 0.61. Baxter International has a twelve month low of $28.33 and a twelve month high of $44.01.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.22%. Baxter International’s dividend payout ratio is presently 340.02%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Stifel Nicolaus cut their price objective on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Citigroup cut their price objective on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Finally, StockNews.com downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $40.90.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.